Role of TROP2-Directed Antibody-Drug Conjugates in Breast Cancer — Issue 2

Описание: 5-Minute Journal Club: Defining the Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Breast Cancer — Issue 2 (Video Interview)

Interview conducted on June 27, 2025, by Dr Neil Love. Featuring an interview with Dr Erika Hamilton. Published August 2025.

Topics:
• Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00)
o Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
• Management protocols for adverse events associated with sacituzumab govitecan (7:49)
o García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101.
o Pérez-García JM et al. Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial. eClinicalMedicine 2025;85:103309. Abstract
• Datopotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease (10:51)
o Tarantino P et al. DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease. ASCO 2025;Abstract TPS1134.
• Sequencing ADCs in breast cancer (13:12)
o Pacholczak-Madej R et al. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochim Biophys Acta Rev Cancer 2025;[Online ahead of print]. Abstract

The complete program, slides, CME information, and selected publications:
https://www.researchtopractice.com/5M...